 |
|
Safety of Pregnancy After Discontinuation of Isotretinoin
Wanju S. Dai, MD, DrPH;
Ming-Ann Hsu, MPH;
Loretta M. Itri, MD
Arch Dermatol. 1989;125(3):362-365.
Abstract
| |
• Isotretinoin (13-cis-retinoic acid, Accutane) increases the risk of major congenital malformations in infants exposed to isotretinoin during pregnancy. However, there have been no epidemiologic reports to date on the effect of a subsequent pregnancy after discontinuation of isotretinoin. This article describes our analysis of pregnancy case reports from patients in whom conception occurred after isotretinoin treatment had been discontinued. Based on the 88 prospectively ascertained cases, the incidence rate of both spontaneous and missed abortions from all pregnancies was 9.1% (eight patients), and the incidence rate of congenital malformation among the live births was 5.0% (four patients). The incidence rates for both these outcomes were not significantly different from the rates reported for women of reproductive age in the general population. In addition, the malformations reported were not characteristic of retinoic acid-induced congenital anomalies.
(Arch Dermatol 1989;125:362-365)
Author Affiliations
From the Department of Drug Safety, Hoffmann-La Roche Inc, Nutley, NJ.
Footnotes
Accepted for publication Sept 19, 1988.
Reprint requests to Department of Drug Safety, Hoffmann-La Roche Inc, 340 Kingsland St, Nutley, NJ 07110 (Dr Dai).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young: Endorsed by the American Academy of Pediatrics
Jenkins et al.
Circulation 2007;115:2995-3014.
ABSTRACT
| FULL TEXT
Isotretinoin (13-cis-retinoic acid; Accutane)
JWatch Pediatrics 2004;2004:10-10.
FULL TEXT
|
